Foresight Biotherapeutics announced today the formation of its scientific advisory board to provide guidance to the company for the development of it’s lead product FST-100, a novel formulation of dexamethasone that includes povidone-iodine. Foresight’s Scientific Advisory Board is comprised of leaders in the field of Ophthalmology.
Originally posted here:
Scientific Advisory Board to provide guidance to support the development of FST-100
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.